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HIV CRF07 B′/C is a strain circulating mainly in northwest region of China. The gp41 region of CRF07 is
derived from a clade C virus. In order to compare the difference of CRF07 gp41 with that of typical clade B
virus, we solved the crystal structure of the core region of CRF07 gp41. Compared with clade B gp41,
CRF07 gp41 evolved more basic and hydrophilic residues on its helix bundle surface. Based on sequence
alignment, a hyper-mutant cluster located in the middle of HR2 heptads repeat was identiﬁed. The
mutational study of these residues revealed that this site is important in HIV mediated cell–cell fusion
and plays critical roles in conformational changes during viral invasion.
& 2013 Elsevier Inc. All rights reserved.Introduction
The viral replication, virus–host interaction, and therapeutic
intervention of human immunodeﬁciency virus (HIV), the etiolo-
gical agent of acquired immune deﬁciency syndrome (AIDS) have
been extensively studied (Gorry and Ancuta, 2011; Murakami and
Yamamoto, 2000; Vandegraaff and Engelman, 2007). There has
been huge progress in the discovery of dozens of inhibitors to
control every step of the life-cycle of HIV (Currier and Havlir, 2009;
Havlir and Currier, 2006; Luetkemeyer et al., 2012). Despite these
advances, however, there is still no way to completely eliminate
the virus from the human body (Garber et al., 2004). Even with the
help of a cocktail of inhibitors, most infected individuals will
eventually lose control over the virus and succumb to secondary
infections (Kadow et al., 2006; Tamamura and Fujii, 2004). Though
clade B HIV was the dominant strain when HIV was ﬁrst isolated
(Bagetta et al., 1999; Barnett et al., 1997; Riabinina et al., 2007),
global spreading of the virus has led to the identiﬁcation of many
other clades and circulating recombination forms (CRF), some ofll rights reserved.
Qiao),which emerged during spread by gene mutation and recombina-
tion (Butler et al., 2007; Peeters and Delaporte, 1999).
HIV relies on gp120 and gp41 to attach to the host cell
membrane (Chazal and Gerlier, 2003; Clapham and McKnight,
2002; Hu et al., 2012; Wilen et al., 2012; Wyatt et al., 1998).
Through the sequential binding of gp120 to the CD4 receptor and
CCR5/CXCR4 co-receptor (Davis et al., 1997), the fusion peptides
buried within the gp120/gp41 trimer are exposed and mediate
membrane fusion between the virion and the host cell (Edinger
and Doms, 1999; Markosyan et al., 2002; Roy et al., 2013; Yee et al.,
2011). Though gp41 is not well-exposed on viral surface, making it
difﬁcult to be targeted by neutralizing antibodies, its high
sequence conservation and, to a lesser extent, glycosylation
pattern make it a good target for broad spectrum neutralizing
antibody induction and vaccine development. Several antibodies
against gp41 in HIV, such as 2F5, 4E10, and 10E8, have already
been identiﬁed and shown to neutralize a wide spectrum of HIV
isolates (Huarte et al., 2011; Pejchal and Wilson, 2010; Phogat and
Wyatt, 2007; Weiss, 2003). Crystal structures of HIV gp41 are
therefore critical in understanding the molecular interactions in
these neutralization events. All reported gp41 structures, even
those with varying helical region lengths, are shown to contain a
stable six-helix bundle, with three N-terminal heptad repeats
(HR1) forming the core of the coiled-coil and the other three
C-terminal heptad repeats (HR2) lining the outside in an
Table 1
X-ray crystallographic data and reﬁnement statistics for the crystal of CRF07 gp41.
Data collection
Space group R32
Wavelength (Å) 0.9793
Unit cell dimensions
a (Å) 46.92
b (Å) 46.92
c (Å) 185.05
α, β, γ (deg) 90, 90, 120
Molecules per ASUa 1
Resolution (Å) b 1.8 (1.98–1.80)
Completeness (%)b 95.76 (92.5)
Redundancyb 11.4 (10.6)
No. of total reﬂections 83,516
No. of unique reﬂections 7326
I/sb 17.5 (2.3)
Rsym
bc 5.3 (31.4)
Reﬁnement statistics
Resolution (Å) 1.8
No. of reﬂections 7326
Rwork/Rfree (%)de 22.01/25.82
No. of atoms
Protein 685
Water 30
B-factors (Å2)
Protein 31.88
Water 38.91
R.m.s. deviations
Bond length (Å) 0.008
Bond angle (deg) 1.226
Ramachandran analysis
Most favored (%) 100.0
Additional allowed (%) 0
Generously allowed (%) 0
Disallowed (%) 0
a ASU¼asymmetric unit.
b Values in parentheses are for the highest resolution shell.
c Rsym¼Σ|I 〈I〉|/Σ〈I〉, where I is the observed intensity, and 〈I〉 is the average
intensity of multiple observations of symmetry related reﬂections.
d R¼Σhkl||Fobs| |Fcalc||/Σhkl|Fobs|.
e Rfree is calculated from 5% of the reﬂections excluded from reﬁnement.
J. Du et al. / Virology 446 (2013) 86–94 87anti-parallel fashion (Chan et al., 1997; Liu et al., 2009; O’Rourke
et al., 2009). Recently, a crystal structure of HIV gp41 containing
the FPPR (fusion peptide proximal region) and MPER (membrane
proximal external region) was also reported (PDB code 27R)
(Buzon et al., 2010).
Due to the lack of proofreading ability of the HIV reverse
transcriptase, many mutations are accumulated and selected for
by the host immune system during virus infection. Gene recombi-
nation also occurs frequently during virus replication (An and
Telesnitsky, 2002; Burke, 1997; Chen et al., 2012; Motomura et al.,
2008; Saksena et al., 1997; Yabar et al., 2012). These factors
contribute to the diversity of circulating virus in a community or
even within a single host. The selection of a speciﬁc sequence of
HIV is a consequence of both the necessity of viral viability and
pressure from the host immune system. The envelope protein,
including the gp120 and gp41 subunits, is the most divergent
protein in HIV. Its adaptation to the unique and changing environ-
ment is crucial for the survival of the virus (Burke, 1997).
The adaption of gp120 and gp41 through changes in both primary
sequence and spatial conformation is not only pivotal for escaping
antibody neutralizing against the virus, but is also critical for the
maintenance of viral infection and replication (Archer et al., 2008).
HIV CRF07 B′/C is a recombined form of virus circulating mainly
in northwest China where the gp41 subunit is derived from a clade
C virus (Bao et al., 2012; Meng et al., 2012; Shao et al., 2012; Song
et al., 2012). Compared to typical clade B viruses, most of differing
residues in the gp41 core region are located within the HR2 heptad
repeat (Matthews et al., 2000; Trivedi et al., 2003; Zhao et al.,
2000). Using the crystal structure reported here, we were able to
localize most of the modiﬁed residues on the surface of the
six-helix bundle. A hyper-mutated site located in the middle of
HR2 was identiﬁed via sequence alignment. Individual point
mutations of these residues suggest that this site is important
for viral infection and adaptation. The hyper-mutated region
affects the stability of viral spikes and interferes with conforma-
tional changes during viral infection. These mutations are com-
plemented with other mutations within gp41 to maintain the full
function of envelope proteins for efﬁcient adaptation during
infection. In this study, the relative conservation of these residues
during evolution is also investigated and the possible conforma-
tional changes associated with these residues on gp41 during viral
infection are discussed.Results
The overall structure of CRF07 gp41
Based on the core structure of clade B, the CRF07 gp41 core
region was subcloned and expressed in Escherichia coli (Chan et al.,
1997). The solubility of CRF07 gp41 is relatively acceptable in
Tris–NaCl buffer and no organic solvent or harsh pH was required
during protein puriﬁcation. A high resolution dataset was collected
on the protein crystal and the structure determined by molecular
replacement using a searching model of clade B (PDB code 1AIK)
(Chan et al., 1997; McCoy, 2007). Results of data processing and
structure determination are summarized in Table 1. Unsurpris-
ingly, the overall structure of CRF07 gp41 is very similar to clade B
gp41, with an r.m.s.d. of Cα of about 1.15 Å. Four additional
residues, derived from the cloning vector (QSND-), preceded
gp41 and formed a continuous helix with HR1 (Fig. 1A). The linker
peptide (GGGGR) between HR1 and HR2 is visible clearly from the
electron density map. Three water molecules were identiﬁed along
the central axis, which formed H-bonds to polar residues from
HR1 (Q552, Q562 and T569), contributing to the stabilization of
the six-helix bundle. Superimposing to other gp41 structures ofvarying lengths shows that the relative orientation and distance
within this six-helix bundle is quite similar, indicating a stable
post-fusion conformation constituted by the core region, despite
minor local conformational changes resulting from different gp41
constructs (Fig. 1B). Compared to typical clade B gp41, the posi-
tions of the buried residues are barely changed despite more than
a dozen residue mutations exist, mainly in HR2. These mutated
residues inﬂuence the solvent accessibility and surface charge of
the six-helix bundle. Overall, the surface of CRF07 is more basic
and hydrophilic due to these mutations (Fig. 1C).
The mutational sites of CRF07 compared with typical clade B
From the sequence alignment of the CRF07 gp41 core region
with that of clade B, 15 differing residues were identiﬁed in total,
most of which are located within the HR2 heptad repeats (Fig. 2A),
consistent with a previous observation that HR2 is more prone to
mutations due to selection pressure of the host immune system
(Aquaro et al., 2006; Ray et al., 2009). To maintain the viability of
the virus, gp41 subunits harboring these mutations must retain
membrane fusion capability during viral infection. In order to
investigate the effect of these mutations from an evolutionary
point of view, the differing residues on CRF07 gp41 were indivi-
dually mutated to the corresponding residues in clade B. The
inﬂuence on cell–cell fusion of these mutations in the context of
CRF07 were detected and summarized in Table 2.
From our results, it is unsurprising that most of the mutations
lead to the decrease, or even abolishment of fusion ability.
Fig. 1. The overall structure of CRF07 gp41. (A) A trimer formed through crystal-
lographic symmetry is shown. For clarity, monomers 2 and 3 are shown in gray. In
monomer 1, HR1 and HR2 region are shown in green and magenta, respectively.
Sequence derived from the expression vector (QSND-) is shown in blue. The linker
(GGGGR) is shown in yellow. Three water molecules coordinated by Gln552,
Gln562, and Thr569 are shown as spheres in red. (B) The structure alignment of
the CRF07 gp41 and clade B gp41. The CRF07 gp41 HR1 and HR2 are shown as in
(A), the clade B gp41 HR1 and HR2 are shown in chartreuse and pink, respectively.
(C) The gp41 surface charge of CRF07 (left) and clade B (right); the blue color means
positive charge and the red color means negative charge.
Fig. 2. The sequence divergence of gp41 between CRF07 and clade B. (A) Sequence
alignment between gp41 of CRF07 and clade B. The invariant residues are shown in
black, the conserved residues in gray and unconserved residues in white. The residues
are shown as stick model and colored according to the element type (N, blue; O, red; C,
yellow). (B) The location of mutation sites in crystal structure. The divergent residues
are shown in sticks, and the backbone ribbon is colored as in Fig. 1A.
Table 2
Cell fusion activity of CRF07 mutants. The vector pcDNA3.1 and wild type gp41 are
negative and positive control, respectively. The results shown are the average of
three independent experiments. And the Tm was calculated with a Boltzmann
sigmoidal ﬁt using OriginLab.
number Mutation site Cell-fusion activity Melting temperature
0 pcDNA3.1 1
1 WT 54.8 75
2 S553N 111 75
3 I559G 0.84 75
4 T578A 2.2 75
5 V580I 21.7 75
6 Q630E 29.3 74
7 K633R 2.4 76
8 S636N 106.5 75
9 N640S 8.5 75
10 T641L 18.5 74
11 V642I 60 75
12 Y643H 11.1 75
13 R644S 13.5 73
14 L645A 1.3 45
15 L646I 2.5 75
16 R655K 38.5 75
17 K658Q 90.9 75
18 D659E 49.7 75
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than a decade, and many of its unique residues are a consequence
of natural selection of the virus and adaptation to the host
environment. The mutations on these residues will reasonablyincur ﬁtness losses for the virus and the reduction in fusion ability
is probably one of these consequences. Three mutations, T578A,
K633R, and L646I, abolished the fusion ability completely
Fig. 3. The hyper-mutant cluster in HR2. (A) Sequence alignment of HR2 of CRF07
with that of other clades. The consensus sequence is shown on top. The invariant
residues are shown in black, the conserved residues in gray and unconserved
residues in white. (B) The position of N640 and L646 in gp41 trimer. N640 and L646
are shown as stick model and colored according to the element type (N, blue; O,
red; C, yellow).
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Interestingly, two mutations, both mutations from Ser to Asn
(S553N and S636N), increase the fusion ability signiﬁcantly
(Table 2). The side chains of both mutations, one from HR1 and
the other from HR2, were projected outwards on the six-helix
bundle of gp41 based on crystal structure, implying the surface
residues are also critical for proper function of gp41.
From the crystal structure reported here, most of the mutated
residues are located on the surface of the six-helix bundle. Their
side chains, except V642I and L646I, protrude outwards and the
corresponding mutations are not predicted to impact the stability
of the helix bundle. To verify this hypothesis, the mutant proteins
were puriﬁed and the stability measured by circular dichroism.
Unsurprisingly, there were only minor changes to the melting
temperature (Tm) of these mutants compared to wild-type CRF07
protein, indicating the alteration of fusion ability here is not due to
changes in stability of the helix bundle (Table 2), although a
correlation has been observed in several other mutants. In sum-
mary, changes in the fusion ability due to mutations in CRF07 gp41
compared to clade B are the consequences of local conformational
changes rather than the perturbing of post-fusion stability of gp41.
By checking the spatial position of mutations which signiﬁ-
cantly inﬂuence fusion and infection, i.e., the three negative
mutants T578A, K633R, L646I and two positive mutants S533N
and S636N, we observed that K633R localized closely to S636N on
the N-terminal half of HR2 (Fig. 2B). The disulﬁde bond loop region
precedes the N-terminal half of HR2 and is, together with the
N-terminus of HR2, presumably involved in the loop-to-helix
transition during conformational change necessary for proper
membrane fusion, a phenomenon observed in several membrane
fusion proteins including gp41. Based on the crystal structure,
T578A is also spatially close to this region (Fig. 2B). The break of
helix and a hairpin structure in HR1, where the N- and C-terminal
halves are aligned in an anti-parallel fashion, has been suggested
in pre-fusion state by Sanders et al. (2002) based on study of I559
mutations. If we take this pre-fusion hairpin structure into con-
sideration, S553N may also be spatially close to this mutation
hotspot prior to membrane fusion (Fig. 2B).
The hyper-mutant cluster in the middle of HR2
The V642I and L646I are the only two mutations identiﬁed to
protrude inward and are likely to interfere with the interaction of
HR1 and HR2 within the six-helix bundle. Valine, isoleucine and
leucine are all hydrophobic residues, so these mutations should be
of little signiﬁcance to the stability of the helix bundle. This
speculation was supported by circular dichroism measurements
of these mutants, which have similar Tm values to that of the wild-
type protein (Table 2). Surprisingly, despite the retention of wild-
type fusion ability by the V642I mutant, there is nearly complete
abolishment of cell–cell fusion with the L646I mutation. Based on
crystal structure, L646 is adjacent to I559 in HR1, a critical position
for gp120–gp41 conformation identiﬁed previously by Sanders
et al. (2002). Accompanying these two mutations, in the middle of
the HR2 helix, a local hyper-mutant cluster of seven consecutive
residues could be identiﬁed based on sequence alignment of
CRF07 and clade B (Fig. 2A). This hyper-mutant stretch was even
more apparent when sequences of different virus clades were
included (Fig. 3A), implying that this region is another mutational
hotspot for virus adaptation during spreading. In the crystal
structure, this region is located within the N-terminal half of
HR2, close to the helix center. All the structures reported for gp41
up to date are in a post-fusion conformation and no structural
information is available in pre- or intermediate state (Buzon et al.,
2010; Chan et al., 1997; Malashkevich et al., 1998; Weissenhorn
et al., 1997). Hypothetically, the gp41 is occluded mostly by gp120within the spike of virus before infection occurs, with its fusion
peptide buried inside (Hu et al., 2011; Mao et al., 2012, 2013; Tran
et al., 2012; Zhu et al., 2008). At this stage, the long helices of HR1
and HR2 observed in crystal structure would only be partially
formed. Based on our cell fusion assay, mutations within this
cluster, in most cases, signiﬁcantly altered the fusion ability of
gp41. From the study above (Results section), we hypothesize the
N-terminal half of HR2 would adopt a partially unstructured
conformation which would exist within the spikes of infectious
virus prior to fusion. To further explore the conformational change
of this region during fusion, we performed a series of single
proline mutations of this region. The introduction of proline,
which would break the continuity of helix, was used by Sanders
et al. (2002) to investigate the conformation of gp140. In their
study, a stable gp140 was generated by a mutation (I559P) within
HR1, suggesting a pre-fusion hairpin structure for HR1. In these
mutations within the hyper-mutation cluster, an obvious loss of
function similar to that of the I559P mutant was observed in the
cell fusion assay (Table 3). One exception, N640P, retains fusion
ability similar to the wild-type, suggesting that the breakdown of
the helix within the N-terminal half of HR2 is not always fatal for
protein function. Measurement of the melting temperature with
circular dichroism showed that the Tm of all mutants decreased
signiﬁcantly (Table 3). The location of this mutation again attracts
our attention to the N-terminal half of HR2, where several critical
mutations, such as K633R, S636N, have been identiﬁed (Fig. 3B).
The tolerance of a proline mutation within this region suggests a
ﬂexible conformation is necessary for proper function of gp41, and
the rigidity of a continuous helix is not always critical for viral
infection.
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To verify the membrane fusion activity of gp41 mutants at the
viral infection level, a pseudo-virus infection system using one-
cycle entry was used to determine the inﬂuence of these muta-
tions on infection (Monteﬁori, 2005; Thayil et al., 2012; Yao et al.,
2012). Three critical mutations identiﬁed above, S553N, S636N and
N640P, were tested. For S553N and S636N, both of which acquired
signiﬁcant increases in membrane fusion activity based on the cell
fusion assay, also showed signiﬁcant increases in viral infection
ability (Fig. 4A), a phenomenon that cannot be attributed to mere
variations in protein expression. For N640P, it is also obvious the
mutation has only a mild effect on viral infection compared with
the wild-type (Fig. 4B). Taken together, our observation of gp41
activity based on cell fusion is reliable and further conﬁrmed by
our results in the pseudo-virus infection system.Table 3
Cell fusion of mutants in hyper-mutated cluster. The vector pcDNA3.1 and wild type
are negative and positive control, respectively. The results shown are the average of
three independent experiments. And the Tm was calculated with a Boltzmann
sigmoidal ﬁt using OriginLab. N/A, no available mutation identiﬁed.
Number Mutation
site
Cell-fusion
activity
Melting
temperature
(1C)
Other mutations found
from database
0 pcDNA3.1 1
1 WT 43.4 75
2 I559P 1.6 42 N/A
3 N640P 34.4 42 S, G, Y, D
4 T641P 3.2 42 I, L, H, E
5 V642P 2 42 I
6 Y643P 2.2 40 H
7 R644P 2.2 42 S, K
8 L645P 2.6 40 N/A
9 L646P 1.9 40 I
Fig. 4. Mutants activity detected by pseudovirus infection. (A) Virus infection using S55
negative and positive control. The expression levels of the mutant ENVs are shown in low
mutant. The pcDNA3.1 and the wild type are used as the negative and positive control, re
average of three independent experiments, and the error bars indicate standard deviatiDiscussion
The crystal structure of gp41 is well-characterized. Following
the determination of the structure of the N36-C34 peptides
comprising the core region (Chan et al., 1997), different lengths
of HR1 and HR2 were constituted intended to reveal the con-
formation along this core region. Recently, the crystal structure of
complete extracellular domain of gp41 lacking the fusion peptide
and cysteine-linked loop (pdb code 27R) was determined
(Buzon et al., 2010). In this crystal, where formation was facilitated
by a high concentration of MPD, both the fusion peptide proximal
region (FPPR) and membrane proximal external region (MPER)
form α-helices along the core region of gp41, indicating a domi-
nant potency to form helices in the residues neighboring the
heptad repeats. Unfortunately, all structures reported to date
characterized by a six-helix bundle conformation are of the post-
fusion state of gp41. The pre-fusion structure of gp41, which is
stabilized by interaction with gp120, is unlikely to be obtained
easily due to the unstable high-energy state. For the purpose of
vaccine development, the detailed conformation of the pre-fusion
state, found in the native spikes of virus, must be urgently
established. This could be explored by investigating the mutations
generated naturally during virus spreading. The virus must retain
the conserved residues for survival; non-essential residues can be
mutated for adaptation purposes. Based on this hypothesis, we
compared the sequence of CRF07 and clade B virus and system-
atically mutated the non-conserved residues to determine their
inﬂuence on viral infection. The crystal structure of CRF07 core
region reported here is similar to gp41 structures from other
clades. By analyzing the consequence of mutations on viral
infection, we could identify a hotspot located within N-terminal
half of HR2. This region is hyper-mutated between different clades
which, despite natural variation among various clades, could lead
to striking consequences (abolishment or increase) on viral infec-
tion. The introduction of proline within this region to disrupt
helix continuity revealed a site where modulation is tolerable,3N and S636N mutants. The plasmid pCDNA3.1 and wild type (WT) are used as the
er panel and the actin used as the loading control. (B) Virus infection using N640P
spectively. The activity of I559P is compared. In both (A) and (B), the results are the
ons.
Fig. 5. Model of gp41 transition during virus–cell membrane fusion. From left to
right, the sequential conformational change needed for HIV gp41 during membrane
fusion is suggested. The representation is just schematic, and detailed features of
gp41 are not incorporated. HR1 and HR2 regions are shown in green and magenta,
respectively. …… means some other possible broken sites in native state gp41.
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effective replication of virus.
Recently, with higher resolution of HIV-1 Env trimer from
single particle cryo-electron microscopy (cryo-EM) (Mao et al.,
2012, 2013; Tran et al., 2012), more details for conformation of
pre-fusion gp41 is characterized. The HR1 helix is formed ﬁrst in
an activated intermediate induced by antibody 17b binding (Tran
et al., 2012) preceding the full pre-hairpin intermediate formation.
While in an unliganded Env trimer without C-terminal intracel-
lular region (Env()ΔCT), 7–8 short α-helices for each gp41
ectodomain are discovered, which is signiﬁcantly different from
the six-helix bundle post-fusion architecture (Mao et al., 2013). All
these information, together with mutational study reported here,
lead to a conclusion of striking conformational change comprising
transition from loop to helix is required for functional gp41 in
membrane fusion process.
The local loop-to-helix transition has been observed in various
membrane fusion proteins, such as HA2, in which the availability
of both pre- and post-fusion structure allow us to depict this kind
of transition in atomic detail (Bosch et al., 1981; Huang et al., 2009;
Lu et al., 2012). The MPER region of gp41 could exist in either
α-helix or an extended loop, depending on the context of the
surroundings or antibody binding, supporting the different struc-
tures observed during various stage of viral infection (Coutant
et al., 2008; Harris et al., 2013; Hartono et al., 2013; Hinz et al.,
2009; Peachman et al., 2010). The length of helix in the extra-
cellular region of the crystal structure extended nearly 80 Å in HIV
gp41 (pdb code 27R) and the length of the helix in SIV gp41
(pdb code 1QBZ) is even longer (Caffrey et al., 1998; Malashkevich
et al., 1998; Yang et al., 1999). As a comparison, the breadth of
gp120 without V1V2 and V3 loops is less than 50 Å in either
dimension (Guttman et al., 2012; Huang et al., 2005; Joyce et al.,
2013; Kwong et al., 1998; Pancera et al., 2010; Wyatt et al., 1998).
It is reasonable to speculate that the helices of gp41 are not fully
assembled in the pre-fusion state within the viral spikes. The
results with the I559P mutant described a possible hairpin
structure for HR1 (Sanders et al., 2002), and mutations within
the N-terminal half of HR2 in our study support the hypothesis
that a ﬂexible or even unstructured loop conformation could exist
within HR2. Based on these observations and recent high resolu-
tion cryo-EM data (Mao et al., 2012, 2013; Tran et al., 2012), we
could propose a pre-fusion model for gp41 in which both HR1 and
HR2 are broken in the middle (or more sites) and a coordinated
loop-to-helix transition is necessary for viral fusion (Fig. 5). HIV
gp41 could go through the following steps to drive membrane
fusion. (a) The gp41 protein in the native conformation, with the
fusion peptide sequestered. In the native state, HR1 and HR2 are
broken in the middle or more sites and a coordinated loop-to-
helix transition is necessary for viral fusion. (b) Transition stage of
the virus–cell membrane fusion. HIV-1 gp41 HR1 and HR2 broken
loop transform to helix and expose the N-terminal fusion peptide.
It seems HR1 assembled ﬁrst prior to HR2 assembly (Tran et al.,
2012). (c) Extended intermediate stage of the fusion. After the
loop-to-helix transition of HIV gp41, the protein opens up, extend-
ing the fusion peptide to interact with the target membrane
bilayer. (d) The post-fusion stage: the C-terminal segment of
gp41 folds back along the outside of the trimer core. The
membrane collapse and bring the two bilayers into contact, then
the bilayers form a fusion pore. Finally, zipping up of the
ectodomain segment snaps the refolded trimer into fully sym-
metric, post fusion conformation.
The tolerance of the N640P mutation in viral infection is
surprising, considering the importance of a stable helix within
HR2 heptad repeat region. In all atomic structures of HIV gp41
reported to date, a helix conformation around the N640 region has
always been present. The viability of virus bearing this mutationindicates a functional envelope spike with proper conformation
during the pre-fusion stage. In contrast to the complete loss of
function in the I559P mutant, the viability of N640P implies that
this mutation is completely tolerable for viral infection. An
envelope spike must undergo a conformational transition from
pre- to intermediate- to post-fusion stages. Our data strongly
suggests that conformational ﬂexibility, even a turn substituted
for a continuous helix around N640, is acceptable. A dramatic
conformational transition, probably from turn/loop to helix, is
postulated at N640, which acts in concert with other conforma-
tional changes in neighboring residues within the hyper-mutation
site (Fig. 4). Due to the lack of structural information about the
pre-fusion state of envelope proteins, immunogen design in
vaccine development efforts based on envelope proteins is tre-
mendously impeded. Our study on the conformational transition
of gp41 should provide useful insights into the mechanism of HIV
infection and vaccine research.Materials and methods
Plasmids and molecular cloning
The ectodomain of CRF07 gp41 was constructed based on the B
subtype HIV gp41 reported previously (Chan et al., 1997). HR1 and
HR2 were connected by a GGGGR linker, HR1-GGGGR-HR2
(GGGGR). Fragments of CRF07 gp41 were ampliﬁed by overlapping
PCR and cloned into the pET30-TEV/LIC expression vector (Nova-
gen, Germany) with a 6His-tag for puriﬁcation, called pET30-
gp41. The HIV ENV protein used in cell–cell fusion was expressed
in eukaryotic expression vector pSRH NLA/S/Av (kindly provided
by Dr. Eric Hunter, Emory University, GA, USA), pSRHS-gp160. The
QuikChange site-directed mutagenesis kit was used to generate
point mutation and amino acid exchanges. The procedure was
performed according to manufacturer's instructions.
Cells culture and transfection
293T, TZM-bl cells and COS-1 cells were maintained in Dulbec-
co's modiﬁed Eagle's medium (DMEM) with 10% FBS (fetal bovine
serum), penicillin (50 U/ml) and streptomycin (50 mg/ml). Cells
were maintained in a humidiﬁed atmosphere containing 5% CO2 at
37 1C. The 293T and COS-1 cells were transfected by lipofecta-
mine2000 (Invitrogen, USA) according to the manufacturer's
instructions.
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Gp41 was expressed in E. coli strain Rosetta (DE3) in Luria broth
(LB) medium (50 μg/ml kanamycin). The culture was induced with
400 μM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 8 h at
20 1C for protein expression. Cells were harvested by centrifuga-
tion (6000g, 10 min, 20 1C) and resuspended in buffer A (50 mM
Tris pH 8.0, 500 mM NaCl). Cells were lysed by sonication and the
crude cell extract clariﬁed by centrifugation (38,000g, 4 1C, 40 min).
The supernatant was applied to Ni–NTA resin equilibrated in
buffer A (50 mM Tris pH 8.0, 500 mM NaCl). The column was
washed with 5 column volumes (CV) of buffer A containing 40 mM
imidazole. Proteins bound to the columnwere eluted with buffer A
containing 500 mM imidazole. The protein was further puriﬁed
using a HiTrap Q HP column (GE Healthcare) with a linear gradient
of NaCl from 100–1000 mM. Peak fractions eluted from the
column were puriﬁed using a Superdex-200 gel ﬁltration column
(GE Healthcare) and adjusted to a ﬁnal protein concentration of
8 mg/ml. The purity of the protein was determined to be 498% as
analyzed by SDS-PAGE and Coomassie blue staining (data not shown).
Crystal grow, data collection and structure determination
Crystals of CRF07 gp41 were grown using the sitting-drop
vapor diffusion method at 4 1C by mixing equal volumes (1 μl
each) of the protein solution (at 8 mg/ml in 20 mM Tris pH 8.0,
500 mM NaCl) and the reservoir solution (8% PEG6000, 0.1 M Tris,
pH 8.5, 40% MPD). Before data collection, crystals were ﬂash frozen
at 100 K with parafﬁn oil as cryoprotectant. Data was collected at
100 K using a wavelength of 0.9793 Å in Shanghai Synchrotron
Radiation Facility, and processed in HKL2000 package
(Otwinowski and Minor, 1997). Data collection and processing
results are summarized in Table 1.
For the structure determination, the structure of clade B gp41
(PDB code 1AIK) was used for molecular replacement. The Phenix
reﬁnement program (phenix.reﬁne) was used for reﬁnement
(Adams et al., 2010). Simulated annealing, positional reﬁnement
and B-factor reﬁnement were used in multiple rounds to improve
the quality of the structure. Ordered water molecules were added
to the structure in the last round of reﬁnement. Reﬁnement
statistics are summarized in Table 1.
Circular dichroism spectroscopy
The protocol was adapted from a previously published method
(Pozdnyakova and Regan, 2005). Brieﬂy, CD measurements were
performed using a Biologic M450 (BioLogic science In., France)
Spectropolarimeter equipped with a thermoelectric temperature
controller. Spectra of each protein were measured at 5 1C in 1 nm
steps from 190 to 260 nm in PBS buffer. For thermal denaturation
experiments, the ellipticity was measured at 222 nm with 1 1C
steps from 5 1C to 95 1C at a rate of 90 1C/h. Thermal melting (Tm)
points were calculated with a Boltzmann sigmoidal ﬁt using
OriginLab.
Cell–cell fusion assay
COS-1 cells in six-well plates were transfected with pSRHS-
gp160 (1.5 mg/well). Cells transfected with pcDNA3.1 (1.5 mg/well)
were used as negative control. After culturing for 24 h, transfected
COS-1 cells were removed using trypsin, washed, and resuspended
in fresh medium. To initiate cell–cell fusion, equal numbers of
TZM-bl cells were overlaid on conﬂuent COS-1 in 12-well plates
and coincubated at 37 1C overnight. After coincubation, the cells
were washed and lysed in reporter lysis buffer (100 ml/well), andassayed for luciferase activity according to manufacturer’s instruc-
tions (Promega, USA)Pseudo-virus generation and fusion activity test
HIV-1 pseudo-viruses were produced in 293T cells by co-
transfection of pNL4-3-ENV-Luc+ and HIV-1 envelope expression
vectors pSRHS-gp160 using the Lipofectamine2000 Transfection
System (Invitrogen, USA). HIV-1 pseudo-virus was harvested in
culture supernatants at 48 h post-transfection. Supernatants were
clariﬁed by centrifuging at 1500g for 10 min. Virus titer was
determined by ELISA (Biomerieux, France) to quantify viral p24.
The fusion activity of the pseudo-virus was measured the lucifer-
ase activity through adding the virus to TZM-bl cell line, the
procedure just like the cell–cell fusion test. 24 h post-infection, the
TZM-bl cells were washed and lysed in reporter lysis buffer
(100 ml/well), and assayed for luciferase activity according to
manufacturer's instructions (Promega, USA).Western blotting
To analysis Env protein expression, transfected COS-1 cells
were lysed with NP-40 lysis buffer, containing 1% PMSF, for
30 min on ice. After centrifugation (10,000g, 10 min, 4 1C), the
supernatant was separated by SDS-PAGE. Proteins were trans-
ferred to PVDF membrane (GE Healthcare) for 1 h at 100 V, 4 1C in
a Mini Transblot apparatus from BioRad. The membrane was
blocked in 5% non-fat milk (in PBS buffer) for 45 min at RT (room
temperature) to quench unspeciﬁc binding. Primary antibody was
usually diluted 1:5000 in blocking buffer and incubated 90 min at
RT or overnight at 4 1C. Membranes were washed 4 times for 5 min
each. The appropriate horse radish peroxidase-conjugated second-
ary antibody was diluted 1:8000 in blocking buffer and applied to
the membrane for 45 min at RT. Protein bands were detected using
enhanced chemiluminescence reagents (Millipore) and visualized
on Kodak Scientiﬁc Imaging Film.Accession number
Atomic coordinates and structure factors have been deposited
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